FDA approves use of ibrutinib in combination with rituximab as first line treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma

Approval was based on phase III E1912 trial in patients aged 70 years or younger, which reported progression-free survival of 88% at 37 months compared to 75% in patients receiving fludarabine, cyclophosphamide and rituximab.


Biospace Inc.